Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 340

1.

An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer.

Faugeroux V, Lefebvre C, Pailler E, Pierron V, Marcaillou C, Tourlet S, Billiot F, Dogan S, Oulhen M, Vielh P, Rameau P, NgoCamus M, Massard C, Laplace-Builhé C, Tibbe A, Taylor M, Soria JC, Fizazi K, Loriot Y, Julien S, Farace F.

Eur Urol Oncol. 2019 Jan 4. pii: S2588-9311(18)30213-X. doi: 10.1016/j.euo.2018.12.005. [Epub ahead of print]

PMID:
31412010
2.

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O.

JAMA Oncol. 2019 Jun 6. doi: 10.1001/jamaoncol.2019.1022. [Epub ahead of print]

PMID:
31169866
3.

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor.

Henon C, Blay JY, Massard C, Mir O, Bahleda R, Dumont S, Postel-Vinay S, Adam J, Soria JC, Le Cesne A.

Ann Oncol. 2019 May 22. pii: mdz160. doi: 10.1093/annonc/mdz160. [Epub ahead of print] No abstract available.

PMID:
31114851
4.

Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology.

Salgado R, Solit DB, Rimm DL, Bogaerts J, Canetta R, Lively T, Lyerly K, Span PN, Bateman-House A, Makady A, Bergmann L, Nagai S, Smith C, Robson M, Savage M, Voest E, Sweeney C, Lambin P, Thomas M, Harris L, Lacombe D, Massard C; IBCD-Faculty.

Eur J Cancer. 2019 Jun;114:128-136. doi: 10.1016/j.ejca.2019.03.025. Epub 2019 May 3.

PMID:
31060925
5.

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential.

Baldini C, Champiat S, Vuagnat P, Massard C.

Onco Targets Ther. 2019 Apr 3;12:2505-2512. doi: 10.2147/OTT.S141040. eCollection 2019. Review.

6.

Molecular Survey of Bartonella Species in Shelter Cats in Rio De Janeiro: Clinical, Hematological, and Risk Factors.

Raimundo JM, Guimarães A, Amaro GM, da Silva AT, Botelho CFM, Massard CL, de Lemos ERS, Favacho ARM, Baldani CD.

Am J Trop Med Hyg. 2019 Jun;100(6):1321-1327. doi: 10.4269/ajtmh.18-0585.

PMID:
31017080
7.

Molecular epidemiology of Babesia vogeli in dogs from the southeastern region of Rio de Janeiro, Brazil.

Paulino PG, Pires MS, da Silva CB, Peckle M, da Costa RL, Vitari GLV, de Abreu APM, Massard CL, Santos HA.

Vet Parasitol Reg Stud Reports. 2018 Aug;13:160-165. doi: 10.1016/j.vprsr.2018.06.004. Epub 2018 Jun 19.

PMID:
31014866
8.

Serological and molecular diagnosis of Ehrlichia canis and associated risk factors in dogs domiciled in western Cuba.

Navarrete MG, Cordeiro MD, Silva CB, Massard CL, López ER, Rodríguez JCA, Ribeiro CCDU, Rodríguez OF, Fonseca AH.

Vet Parasitol Reg Stud Reports. 2018 Dec;14:170-175. doi: 10.1016/j.vprsr.2018.10.005. Epub 2018 Oct 29.

PMID:
31014724
9.

Exploring the optimal use of alectinib.

Enrico D, Massard C, Besse B.

Lancet Respir Med. 2019 May;7(5):373-374. doi: 10.1016/S2213-2600(19)30117-1. Epub 2019 Apr 15. No abstract available.

PMID:
31000476
10.

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.

Even C, Lassen U, Merchan J, Le Tourneau C, Soria JC, Ferte C, Ricci F, Diener JT, Yuen E, Smith C, Oakley GJ 3rd, Benhadji KA, Massard C.

Invest New Drugs. 2019 Apr 6. doi: 10.1007/s10637-019-00739-x. [Epub ahead of print]

PMID:
30953269
11.

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.

Massard C, Soria JC, Krauss J, Gordon M, Lockhart AC, Rasmussen E, Upreti VV, Patel S, Ngarmchamnanrith G, Henary H.

Cancer Chemother Pharmacol. 2019 Jun;83(6):1057-1063. doi: 10.1007/s00280-019-03796-4. Epub 2019 Mar 26.

PMID:
30915497
12.

Genetic Diversity of Theileria equi From Horses In Different Regions of Brazil Based On the 18S rRNA Gene.

Vitari GLV, Costa RL, Abreu APM, Peckle M, Silva CB, Paulino PG, Pires MS, Massard CL, Santos HA.

J Parasitol. 2019 Feb;105(1):186-194.

PMID:
30817219
13.

10PSafety profile of epigenetic therapies in early phase trials: Do epidrugs deserve specific drug development processes?

Leroy L, Satar T, Baldini C, Martin-Romano P, Hollebecque A, Michot JM, Ribrag V, Massard C, Paoletti X, Postel Vinay S.

Ann Oncol. 2019 Feb 1;30(Supplement_1). pii: mdz029.003. doi: 10.1093/annonc/mdz029.003. No abstract available.

PMID:
30810172
14.

3OApplicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials.

Varga A, Bernard-Tessier A, Auclin E, Mezquita Pérez L, Baldini C, Planchard D, Marabelle A, Hollebecque A, Besse B, Massard C.

Ann Oncol. 2019 Feb 1;30(Supplement_1). pii: mdz027.001. doi: 10.1093/annonc/mdz027.001. No abstract available.

PMID:
30810169
15.

A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment.

Vicier C, Baciarello G, Arfi-Rouche J, Massard C, Loriot Y, Albiges L, Cojean-Zelek I, Fizazi K.

Clin Genitourin Cancer. 2019 Jun;17(3):e485-e487. doi: 10.1016/j.clgc.2019.01.010. Epub 2019 Jan 26. No abstract available.

PMID:
30792009
16.

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.

Segal NH, Ou SI, Balmanoukian A, Fury MG, Massarelli E, Brahmer JR, Weiss J, Schöffski P, Antonia SJ, Massard C, Zandberg DP, Khleif SN, Xiao F, Rebelatto MC, Steele KE, Robbins PB, Angra N, Song X, Abdullah S, Butler M.

Eur J Cancer. 2019 Mar;109:154-161. doi: 10.1016/j.ejca.2018.12.029. Epub 2019 Feb 4.

PMID:
30731276
17.

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.

Postel-Vinay S, Herbschleb K, Massard C, Woodcock V, Soria JC, Walter AO, Ewerton F, Poelman M, Benson N, Ocker M, Wilkinson G, Middleton M.

Eur J Cancer. 2019 Mar;109:103-110. doi: 10.1016/j.ejca.2018.12.020. Epub 2019 Jan 31.

PMID:
30711772
18.

Molecular characterization of Ehrlichia canis from naturally infected dogs from the state of Rio de Janeiro.

da Costa RL, Paulino PG, da Silva CB, Vitari GLV, Peixoto MP, de Abreu APM, Santos HA, Massard CL.

Braz J Microbiol. 2019 Jan;50(1):1-12. doi: 10.1007/s42770-018-0020-7. Epub 2018 Dec 11.

PMID:
30637653
19.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Cortes J, Massard C, Armand JP, Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier JF, Beliveau M, Martell RE, Baselga J.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy532. [Epub ahead of print] No abstract available.

PMID:
30624604
20.

Immunothérapie des glioblastomes.

Baldini C, Romano PM, Varga A, Champiat S, Dumont S, Dhermain F, Louvel G, Marabelle A, Postel-Vinay S, Angevin E, Gazzah A, Ribrag V, Bahleda R, Michot JM, Hollebecque A, Soria JC, Massard C.

Bull Cancer. 2018 Dec;105 Suppl 1:S59-S67. doi: 10.1016/S0007-4551(18)30391-6. Review. French.

PMID:
30595200
21.

Cancer du rein : tendances et perspectives.

Mery B, Thiery-Vuillemin A, Massard C, Albiges L, Magné N.

Bull Cancer. 2018 Dec;105 Suppl 3:S219-S220. doi: 10.1016/S0007-4551(18)30375-8. French.

PMID:
30595149
22.

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.

Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4.

PMID:
30528137
23.

Focus on the Number of Radiation Oncology Trials or on Clinical Relevance?

Chargari C, Massard C, Deutsch E.

JAMA Oncol. 2018 Dec 1;4(12):1791. doi: 10.1001/jamaoncol.2018.5116. No abstract available.

PMID:
30383141
24.

First record of Bulimulus tenuissimus (Mollusca) as potential experimental intermediate host of Angiostrongylus cantonensis (Nematoda).

Martins FG, Garcia JS, Torres EJL, Santos MAJ, Massard CL, Pinheiro J.

Braz J Biol. 2019 Oct-Dec;79(4):686-696. doi: 10.1590/1519-6984.188914. Epub 2018 Oct 29.

25.

Hyperprogressive disease: recognizing a novel pattern to improve patient management.

Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, Ferté C.

Nat Rev Clin Oncol. 2018 Dec;15(12):748-762. doi: 10.1038/s41571-018-0111-2. Review.

PMID:
30361681
26.

Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

Watson S, Menis J, Baldini C, Martin-Romano P, Michot JM, Hollebecque A, Armand JP, Massard C, Soria JC, Postel-Vinay S, Paoletti X.

Br J Cancer. 2018 Oct;119(8):937-939. doi: 10.1038/s41416-018-0245-0. Epub 2018 Oct 17.

PMID:
30327567
27.

Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen.

Gravis G, Billon E, Baldini C, Massard C, Hilgers W, Delva R, Walz J, Pignot G, Rybikowski S, Dermeche S, Thomassin J, Brunelle S, Lavaud P, Loriot Y; French Genito-Urinary Tumor Group (GETUG).

Eur J Cancer. 2018 Nov;104:236-238. doi: 10.1016/j.ejca.2018.09.002. Epub 2018 Oct 11. No abstract available.

PMID:
30316610
28.

Epidemiology of Ehrlichia canis in healthy dogs from the Southeastern region of the state of Rio de Janeiro, Brazil.

Paulino PG, Pires MS, da Silva CB, Peckle M, da Costa RL, Vitari GV, Vilela JAR, de Abreu APM, Massard CL, Santos HA.

Prev Vet Med. 2018 Nov 1;159:135-142. doi: 10.1016/j.prevetmed.2018.09.012. Epub 2018 Sep 14.

PMID:
30314776
29.

Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation.

Gauci ML, Lanoy E, Champiat S, Caramella C, Ammari S, Aspeslagh S, Varga A, Baldini C, Bahleda R, Gazzah A, Michot JM, Postel-Vinay S, Angevin E, Ribrag V, Hollebecque A, Soria JC, Robert C, Massard C, Marabelle A.

Clin Cancer Res. 2019 Feb 1;25(3):946-956. doi: 10.1158/1078-0432.CCR-18-0793. Epub 2018 Oct 8.

PMID:
30297458
30.

Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?

Prud'homme C, Deschamps F, Allorant A, Massard C, Hollebecque A, Yevich S, Ngo-Camus M, Gravel G, Nicotra C, Michiels S, Scoazec JY, Lacroix L, Solary E, Soria JC, De Baere T, Tselikas L.

Eur J Cancer. 2018 Nov;103:108-119. doi: 10.1016/j.ejca.2018.08.003. Epub 2018 Sep 14.

PMID:
30223224
31.

Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.

Mir O, Azaro A, Merchan J, Chugh R, Trent J, Rodon J, Ohnmacht U, Diener JT, Smith C, Yuen E, Oakley GJ 3rd, Le Cesne A, Soria JC, Benhadji KA, Massard C.

Eur J Cancer. 2018 Nov;103:88-97. doi: 10.1016/j.ejca.2018.08.012. Epub 2018 Sep 12.

PMID:
30218977
32.

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.

Peltola KJ, Bono P, Jones RH, Vjaters E, Nykänen P, Vuorela A, Oksala R, Pohjanjousi P, Mustonen MVJ, Fizazi K, Massard C.

Eur Urol Focus. 2018 Sep 4. pii: S2405-4569(18)30241-4. doi: 10.1016/j.euf.2018.08.022. [Epub ahead of print]

33.

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C.

Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14.

PMID:
30120041
34.

Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors.

Koeppel F, Bobard A, Lefebvre C, Pedrero M, Deloger M, Boursin Y, Richon C, Chen-Min-Tao R, Robert G, Meurice G, Rouleau E, Michiels S, Massard C, Scoazec JY, Solary E, Soria JC, André F, Lacroix L.

Cancer J. 2018 Jul/Aug;24(4):153-162. doi: 10.1097/PPO.0000000000000322. Review.

PMID:
30119077
35.

Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic.

Patrikidou A, Maroun P, Patard JJ, Baumert H, Albiges L, Massard C, Loriot Y, Escudier B, Di Palma M, Arfi-Rouche J, Rocher L, Merabet Z, Bossi A, Fizazi K, Blanchard P.

Clin Transl Radiat Oncol. 2018 Jul 6;12:28-33. doi: 10.1016/j.ctro.2018.07.001. eCollection 2018 Aug.

36.

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.

Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2018 Sep;101:160-164. doi: 10.1016/j.ejca.2018.06.005. Epub 2018 Jul 30.

PMID:
30071444
37.

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.

Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR, Yuen ESM, Benhadji KA, Rodon J.

Ann Oncol. 2018 Sep 1;29(9):1911-1917. doi: 10.1093/annonc/mdy244.

PMID:
30060061
38.

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A, Arranz Arija JA, Shih KC, Radavoi GD, Xu N, Chan WY, Ma H, Gendreau S, Riisnaes R, Patel PH, Maslyar DJ, Jinga V.

Clin Cancer Res. 2019 Feb 1;25(3):928-936. doi: 10.1158/1078-0432.CCR-18-0981. Epub 2018 Jul 23.

PMID:
30037818
39.

First molecular evidence of Babesia caballi and Theileria equi infections in horses in Cuba.

Díaz-Sánchez AA, Pires MS, Estrada CY, Cañizares EV, Del Castillo Domínguez SL, Cabezas-Cruz A, Rivero EL, da Fonseca AH, Massard CL, Corona-González B.

Parasitol Res. 2018 Oct;117(10):3109-3118. doi: 10.1007/s00436-018-6005-5. Epub 2018 Jul 23.

PMID:
30033488
40.

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.

Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, Gould M, Yang P, Keefe SM, Piha-Paul SA.

Ann Oncol. 2018 Aug 1;29(8):1807-1813. doi: 10.1093/annonc/mdy232.

PMID:
29992241
41.

Occurrences of Ornithocoris toledoi (Cimicidae) on a free-range chicken farm in the state of Rio de Janeiro, Brazil.

Pires MS, Luz HR, Peckle M, Silva CBD, Vitari GLV, Costa RLD, Graciosa MG, Santos HA, Faccini JLH, Massard CL.

Rev Bras Parasitol Vet. 2018 Jul-Sep;27(3):396-400. doi: 10.1590/S1984-296120180036. Epub 2018 Jun 11.

42.

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.

Besle S, Schultz E, Hollebecque A, Varga A, Baldini C, Martin P, Postel-Vinay S, Bahleda R, Gazzah A, Michot JM, Marabelle A, Angevin E, Armand JP, Ribrag V, Soria JC, Massard C.

Eur J Cancer. 2018 Jul;98:17-22. doi: 10.1016/j.ejca.2018.04.019. Epub 2018 May 30.

PMID:
29859337
43.

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C.

J Clin Oncol. 2018 Oct 20;36(30):3007-3014. doi: 10.1200/JCO.2018.78.2292. Epub 2018 May 7.

PMID:
29733771
44.

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica.

Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, Jamme P, Gelli M, Goere D, Lacroix L, Adam J, Heukamp L, Trenta P, Hembrough T, Soria JC, Sternberg C, Ducreux M.

Tumori. 2018 Dec;104(6):NP38-NP41. doi: 10.1177/0300891618763215. Epub 2018 Mar 21.

PMID:
29714649
45.

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

Herin H, Aspeslagh S, Castanon E, Dyevre V, Marabelle A, Varga A, Postel Vinay S, Michot JM, Ribrag V, Gazzah A, Bahleda R, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C.

Eur J Cancer. 2018 May;95:68-74. doi: 10.1016/j.ejca.2018.03.002. Epub 2018 Apr 7.

PMID:
29635146
46.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

47.

Development and validation of a duplex real-time PCR assay for the diagnosis of equine piroplasmosis.

Lobanov VA, Peckle M, Massard CL, Brad Scandrett W, Gajadhar AA.

Parasit Vectors. 2018 Mar 2;11(1):125. doi: 10.1186/s13071-018-2751-6.

48.

Durvalumab in urothelial cancers.

Lavaud P, Hamilou Z, Loriot Y, Massard C.

Expert Rev Anticancer Ther. 2018 Apr;18(4):311-318. doi: 10.1080/14737140.2018.1443812. Epub 2018 Mar 5. Review.

PMID:
29486607
49.

Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130].

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2018 Apr;93:156-157. doi: 10.1016/j.ejca.2018.01.077. Epub 2018 Feb 14. No abstract available.

PMID:
29454743
50.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684

Supplemental Content

Loading ...
Support Center